OBJECTIVE： To study the alleviation effect of nervonic acid on movement disorder of model mice with Parkinson’s disease （PD）. METHODS： Mice were randomly divided into blank control group （normal suline）， model group （normal saline）， Levodopa and benserazide hydrochloride tablet group （positive control， calculated by L-dopamine 120 mg/kg）， nervonic acid low-dose， medium-dose， high-dose groups （20.0， 40.0， 80.0 mg/kg）， 10 in each group. Except for blank control group， mice in other groups were inducced for PD models. After modeling， mice were intragastrically given relevant medicines， once a day， for 14 d. After the last administration， behavioral changes of mice in each group were observed. HPLC was conducted to detect dopamine （DA） and its metabolites dihydroxybenzoic acid （DOPAC）， homovanillic acid （HVA） concentrations in the striatum of mice. RESULTS： Compared with blank control group， climbing time was extended in model group， drum time was shortened， spontaneous movement times was decreased， and DA， DOPAC， HVA contents in the striatum were reduced （P＜0.05）. Compared with model group， climbing time was shortened in Levodopa and benserazide hydrochlo ride tablet group， nervonic acid dose groups， drum time was extended， and DA， DOPAC， HVA contents in the striatum were increased （P＜0.05）； and spontaneous movement times was increased in Levodopa and benserazide hydrochloride tablet group， and nervonic acid high-dose group （P＜0.05）. CONCLUSIONS： Nervonic acid can effectively improve symptoms of movement dysfunction of model mice with PD. The mechanism may associate with increasing DA content in the striatum.